Friday, January 18, 2019 12:29:25 PM
The first thing that comes to mind is the partnership to develop the Univec cannabis transdermal patch would have to be described along with the potential target market. Both these topics are material information, and they would need to be described and explained. In addition, any payment either to Dalton or from Dalton to other business entities would also have to be listed. The problem with these disclosures (which currently are not necessary for a non-reporting company) is that they could reveal information that might jeopardize current plans and negotiations. Frustrating to say the least, but understandable.
Like everyone else, I sure would like to see more information, but our only recourse is to buy or sell based on our own research and convictions.
Meanwhile, if Dalton is successful, the potential gains for even small time penny stock investors is astronomical. The choice is yours.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM